Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependent pathways and is attenuated by interferon-γ

Svitlana Demyanets(Medical University of Vienna), Johann Wojta(Medical University of Vienna), Philipp J. Hohensinner(Ludwig Boltzmann Institute for Age Research), Stefan Kastl(Medical University of Vienna), Taras Afonyushkin(CeMM Research Center for Molecular Medicine), Gerald Maurer(European Society of Radiology), Stefan Pfaffenberger(Medical University of Vienna), Katharina M. Katsaros(Medical University of Vienna), Kathrin Rychli(University of Veterinary Medicine Vienna), Kurt Huber(Sigmund Freud Privatuniversität Wien), Matthias Paireder(Barmherzige Schwestern Krankenhaus Wien), Valery N. Bochkov(Medical University of Vienna), Christoph Kaun(University of Vienna), I. Huk(Medical University of Vienna), Gersina Rega‐Kaun(Medical University of Vienna)
Basic Research in Cardiology
December 20, 2010
10.1007/s00395-010-0141-0
Cited by 73

Related Papers

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
|Circulation|2011|1.1k
Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
|New England Journal of Medicine|2011|877
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
|The Lancet|2018|793
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|755